Cargando…
Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial
OBJECTIVE: To determine whether communicating personalised statin therapy-effects obtained by prognostic algorithm leads to lower decisional conflict associated with statin use in patients with stable cardiovascular disease (CVD) compared with standard (non-personalised) therapy-effects. DESIGN: Hyp...
Autores principales: | Jaspers, Nicole E M, Visseren, Frank L J, van der Graaf, Yolanda, Smulders, Yvo M, Damman, Olga C, Brouwers, Corline, Rutten, Guy E H M, Dorresteijn, Jannick A N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287608/ https://www.ncbi.nlm.nih.gov/pubmed/34272216 http://dx.doi.org/10.1136/bmjopen-2020-041673 |
Ejemplares similares
-
Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
por: Berkelmans, Gijs F. N., et al.
Publicado: (2020) -
Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives
por: Jaspers, Nicole E M, et al.
Publicado: (2018) -
A new selection method to increase the health benefits of CVD prevention strategies
por: Lagerweij, Ghizelda R, et al.
Publicado: (2018) -
Prediction and personalised treatment of atrial fibrillation—stroke prevention: consolidated position paper of CVD professionals
por: Helms, Thomas M, et al.
Publicado: (2014) -
Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients
por: Stam‐Slob, Manon C., et al.
Publicado: (2017)